Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free PRLD Stock Alerts

Prelude Therapeutics (PRLD) Financials

Prelude Therapeutics logo
$4.91 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.80 -0.11 (-2.18%)
As of 07/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Prelude Therapeutics

Annual Income Statements for Prelude Therapeutics

This table shows Prelude Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -28 -57 -112 -115 -122 -127 -99
Consolidated Net Income / (Loss)		 -28 -57 -112 -115 -122 -127 -99
Net Income / (Loss) Continuing Operations		 -28 -57 -112 -115 -122 -127 -99
Total Pre-Tax Income 		-28 -57 -112 -115 -132 -127 -99
Total Operating Income		 -28 -59 -114 -124 -132 -140 -105
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 7.00 12
Total Revenue		 0.00 0.00 0.00 0.00 0.00 7.00 12
Operating Revenue		 - - - - 0.00 7.00 12
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 28 59 114 124 132 147 117
Selling, General & Admin Expense		 3.83 11 27 31 29 29 22
Research & Development Expense		 24 48 87 93 103 118 94
Total Other Income / (Expense), net		 0.54 1.83 2.04 8.10 0.00 13 5.07
Other Income / (Expense), net		 0.54 1.83 2.04 8.10 - 13 5.07
Basic Earnings per Share		 ($16.52) ($4.56) ($2.43) ($2.44) ($2.02) ($1.68) ($1.29)
Weighted Average Basic Shares Outstanding		 1.67M 12.48M 46.05M 47.37M 60.36M 75.81M 76.96M
Diluted Earnings per Share		 ($16.52) ($4.56) ($2.43) ($2.44) ($2.02) ($1.68) ($1.29)
Weighted Average Diluted Shares Outstanding		 1.67M 12.48M 46.05M 47.37M 60.36M 75.81M 76.96M
Weighted Average Basic & Diluted Shares Outstanding		 1.67M 12.48M 46.05M 47.91M 54.92M 55.15M 63.00M

Quarterly Income Statements for Prelude Therapeutics

This table shows Prelude Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -31 -33 -31 -35 -32 -29 -32 -31 -20 -16 -10
Consolidated Net Income / (Loss)		 -31 -33 -31 -35 -32 -29 -32 -31 -20 -16 -10
Net Income / (Loss) Continuing Operations		 -31 -33 -31 -35 -32 -29 -32 -31 -20 -16 -10
Total Pre-Tax Income 		-31 -44 -31 -35 -32 -41 -32 -31 -20 -16 -10
Total Operating Income		 -33 -37 -34 -37 -34 -34 -35 -32 -20 -17 -14
Total Gross Profit		 0.00 - 0.00 0.00 3.00 4.00 0.00 0.00 6.50 5.64 4.58
Total Revenue		 0.00 - 0.00 0.00 3.00 4.00 0.00 0.00 6.50 5.64 4.58
Operating Revenue		 0.00 - 0.00 0.00 3.00 - 0.00 0.00 6.50 5.64 4.58
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 33 37 34 37 37 38 35 32 27 23 19
Selling, General & Admin Expense		 7.12 7.05 6.93 7.66 7.92 6.21 5.79 6.41 5.21 5.00 5.16
Research & Development Expense		 26 30 27 30 29 32 29 26 22 18 14
Total Other Income / (Expense), net		 2.78 -6.14 2.91 2.42 2.11 -7.44 2.52 0.96 0.69 0.89 3.79
Other Income / (Expense), net		 2.78 - 2.91 2.42 2.11 - 2.52 0.96 0.69 0.89 3.79
Basic Earnings per Share		 ($0.45) ($0.45) ($0.42) ($0.46) ($0.43) ($0.37) ($0.42) ($0.41) ($0.26) ($0.20) ($0.13)
Weighted Average Basic Shares Outstanding		 67.64M 60.36M 75.74M 75.76M 75.86M 75.81M 75.99M 75.99M 76.13M 76.96M 82.52M
Diluted Earnings per Share		 ($0.45) ($0.45) ($0.42) ($0.46) ($0.43) ($0.37) ($0.42) ($0.41) ($0.26) ($0.20) ($0.13)
Weighted Average Diluted Shares Outstanding		 67.64M 60.36M 75.74M 75.76M 75.86M 75.81M 75.99M 75.99M 76.13M 76.96M 82.52M
Weighted Average Basic & Diluted Shares Outstanding		 54.83M 54.92M 54.93M 55.02M 55.04M 55.15M 56.46M 56.60M 62.87M 63.00M 79.65M

Annual Cash Flow Statements for Prelude Therapeutics

This table details how cash moves in and out of Prelude Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.28 199 -182 -1.22 -8.11 -13 22
Net Cash From Operating Activities		 -26 -46 -84 -84 -107 -103 -56
Net Cash From Continuing Operating Activities		 -26 -46 -84 -84 -107 -103 -56
Net Income / (Loss) Continuing Operations		 -28 -57 -112 -115 -122 -127 -99
Consolidated Net Income / (Loss)		 -28 -57 -112 -115 -122 -127 -99
Depreciation Expense		 0.38 0.54 0.92 1.32 1.17 1.77 1.71
Amortization Expense		 - 0.00 1.36 2.59 -3.47 -4.64 -0.37
Non-Cash Adjustments To Reconcile Net Income		 0.86 5.59 22 27 28 23 13
Changes in Operating Assets and Liabilities, net		 0.67 4.62 3.63 0.93 -10 4.22 28
Net Cash From Investing Activities		 -0.78 -0.62 -264 82 -35 90 53
Net Cash From Continuing Investing Activities		 -0.78 -0.62 -264 82 -35 90 53
Purchase of Property, Plant & Equipment		 -0.78 -0.62 -2.32 -3.02 -3.51 -0.76 -0.07
Purchase of Investments		 - 0.00 -261 -119 -222 -53 -101
Sale and/or Maturity of Investments		 - - 0.00 204 191 144 154
Net Cash From Financing Activities		 30 246 165 0.82 136 -0.12 25
Net Cash From Continuing Financing Activities		 30 246 165 0.82 134 -0.12 25
Repurchase of Common Equity		 0.00 -0.01 -0.30 - -2.80 -0.11 0.00
Issuance of Common Equity		 0.00 167 162 0.43 136 0.38 25
Other Financing Activities, net		 0.01 0.10 3.50 0.39 0.03 -0.39 -0.21

Quarterly Cash Flow Statements for Prelude Therapeutics

This table details how cash moves in and out of Prelude Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -11 6.60 -0.58 3.12 -17 1.34 28 -15 21 -12 -14
Net Cash From Operating Activities		 -26 -24 -32 -23 -27 -21 -34 -26 -19 23 -22
Net Cash From Continuing Operating Activities		 -26 -24 -32 -23 -27 -21 -34 -26 -19 23 -22
Net Income / (Loss) Continuing Operations		 -31 -33 -31 -35 -32 -29 -32 -31 -20 -16 -10
Consolidated Net Income / (Loss)		 -31 -33 -31 -35 -32 -29 -32 -31 -20 -16 -10
Depreciation Expense		 0.28 0.33 0.43 0.45 0.41 0.49 0.44 0.43 0.43 0.42 0.39
Amortization Expense		 -1.60 -1.07 -1.54 -1.33 -0.82 -0.95 0.08 -0.21 -0.05 -0.19 -0.39
Non-Cash Adjustments To Reconcile Net Income		 7.17 6.52 5.96 6.50 6.32 4.16 4.22 4.20 2.81 2.23 2.39
Changes in Operating Assets and Liabilities, net		 -0.93 3.72 -5.21 6.07 -0.93 4.29 -6.88 0.74 -2.57 37 -14
Net Cash From Investing Activities		 15 7.74 31 26 11 22 62 12 40 -60 8.50
Net Cash From Continuing Investing Activities		 15 7.74 31 26 11 22 62 12 40 -60 8.50
Purchase of Property, Plant & Equipment		 -0.59 -1.13 -0.29 -0.36 -0.06 -0.05 -0.05 -0.02 - - 0.00
Purchase of Investments		 -34 -59 -5.49 -7.88 -32 -7.33 -9.46 -25 - -67 0.00
Sale and/or Maturity of Investments		 50 68 37 34 43 29 72 36 40 6.40 8.50
Net Cash From Financing Activities		 0.09 25 -0.01 0.06 -0.13 -0.03 -0.16 0.04 -0.01 25 -0.31
Net Cash From Continuing Financing Activities		 0.09 22 -0.01 0.06 -0.13 -0.03 -0.16 0.04 -0.01 25 -0.31
Repurchase of Common Equity		 - -2.80 0.00 -0.08 -0.03 - 0.00 - - - -0.29
Other Financing Activities, net		 -0.02 0.02 -0.01 -0.11 -0.11 -0.16 -0.16 -0.06 -0.01 0.01 -0.02

Annual Balance Sheets for Prelude Therapeutics

This table presents Prelude Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 224 305 221 278 176 141
Total Current Assets		 20 221 295 204 236 136 106
Cash & Equivalents		 19 218 32 31 25 12 35
Short-Term Investments		 - 0.00 259 171 208 121 68
Prepaid Expenses		 1.35 2.50 3.88 2.65 2.65 2.28 2.48
Plant, Property, & Equipment, net		 1.65 2.48 3.93 4.91 7.33 6.77 5.11
Total Noncurrent Assets		 0.00 0.30 6.05 11 35 33 31
Other Noncurrent Operating Assets		 0.00 0.30 6.05 11 35 33 31
Total Liabilities & Shareholders' Equity		 22 224 305 221 278 176 141
Total Liabilities		 4.84 11 19 25 41 44 73
Total Current Liabilities		 4.84 11 19 22 22 26 53
Accounts Payable		 1.97 3.92 7.84 6.78 4.58 7.73 3.98
Accrued Expenses		 2.60 7.46 9.62 13 16 15 13
Current Deferred Revenue		 - - - - - 0.00 34
Other Current Liabilities		 - 0.00 1.74 1.83 1.48 2.70 2.74
Total Noncurrent Liabilities		 0.01 0.03 0.00 3.36 19 18 20
Noncurrent Deferred Revenue		 - - - - - 0.00 1.80
Other Noncurrent Operating Liabilities		 0.01 0.03 0.00 3.36 19 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 212 286 195 237 131 69
Total Preferred & Common Equity		 -49 212 286 195 237 131 69
Total Common Equity		 -49 212 286 195 237 131 69
Common Stock		 1.09 320 506 532 693 715 752
Retained Earnings		 -50 -107 -219 -335 -456 -584 -683
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.71 -1.69 0.22 0.04 0.01

Quarterly Balance Sheets for Prelude Therapeutics

This table presents Prelude Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 259 247 224 197 141 115 95 120
Total Current Assets		 235 205 183 156 102 77 58 85
Cash & Equivalents		 16 25 28 11 40 26 48 22
Short-Term Investments		 215 177 152 142 59 47 7.43 60
Prepaid Expenses		 4.41 3.44 2.87 2.76 3.33 3.66 3.37 3.04
Plant, Property, & Equipment, net		 6.62 7.29 7.55 7.20 6.39 5.96 5.53 4.72
Total Noncurrent Assets		 17 34 34 34 32 32 31 30
Other Noncurrent Operating Assets		 17 34 34 34 32 32 31 30
Total Liabilities & Shareholders' Equity		 259 247 224 197 141 115 95 120
Total Liabilities		 20 36 42 41 38 39 36 59
Total Current Liabilities		 17 18 23 22 20 21 18 42
Accounts Payable		 5.17 5.31 6.17 5.92 5.83 4.96 2.53 2.07
Accrued Expenses		 11 10 11 14 11 13 13 5.94
Current Deferred Revenue		 - - 3.00 0.00 0.00 0.00 0.00 31
Other Current Liabilities		 0.48 2.19 2.74 2.72 2.65 2.71 2.73 2.76
Total Noncurrent Liabilities		 3.36 19 19 19 18 18 18 18
Noncurrent Deferred Revenue		 - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 3.36 19 19 19 18 18 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 238 211 182 156 103 76 59 60
Total Preferred & Common Equity		 238 211 182 156 103 76 59 60
Total Common Equity		 238 211 182 156 103 76 59 60
Common Stock		 662 699 705 711 719 723 725 754
Retained Earnings		 -423 -488 -523 -555 -616 -647 -667 -693
Accumulated Other Comprehensive Income / (Loss)		 -0.61 -0.24 -0.29 0.17 0.01 -0.00 0.00 -0.04

Annual Metrics And Ratios for Prelude Therapeutics

This table displays calculated financial ratios and metrics derived from Prelude Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 43,703,381.00 47,215,352.00 47,859,813.00 54,825,982.00 - 62,865,270.00
DEI Adjusted Shares Outstanding		 0.00 43,703,381.00 47,215,352.00 47,859,813.00 54,825,982.00 - 62,865,270.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.30 -2.37 -2.41 -2.22 - -1.58
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 73.43%
EBITDA Growth		 0.00% -107.40% -94.04% -1.93% -20.68% -5.94% 24.52%
EBIT Growth		 0.00% -106.49% -96.20% -3.35% -14.59% -5.62% 21.76%
NOPAT Growth		 0.00% -109.05% -93.55% -8.62% -7.07% -5.62% 25.16%
Net Income Growth		 0.00% -106.49% -96.20% -3.35% -5.54% -4.38% 21.76%
EPS Growth		 0.00% 72.40% 46.71% -0.41% 17.21% 16.83% 23.21%
Operating Cash Flow Growth		 0.00% -79.92% -80.89% -0.24% -27.87% 3.90% 45.28%
Free Cash Flow Firm Growth		 0.00% 0.00% -119.70% -6.37% -20.48% 11.21% 55.43%
Invested Capital Growth		 0.00% -285.28% 12.90% -17.90% 166.05% -151.87% -1,504.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 133.33% 15.62%
EBITDA Q/Q Growth		 0.00% 0.00% -12.81% 2.69% -13.30% -5.88% 18.47%
EBIT Q/Q Growth		 0.00% 0.00% -13.86% 3.51% -12.67% -6.23% 17.80%
NOPAT Q/Q Growth		 0.00% 0.00% -13.54% -0.30% -3.11% 2.48% 13.62%
Net Income Q/Q Growth		 0.00% 0.00% -13.86% 3.51% -3.78% 3.30% 10.98%
EPS Q/Q Growth		 0.00% 0.00% -125.31% 4.69% 6.91% 4.55% 11.64%
Operating Cash Flow Q/Q Growth		 0.00% -16.03% -14.94% 3.21% -0.61% 2.68% 43.79%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 4.12% 1.10% 4.04% 52.31%
Invested Capital Q/Q Growth		 0.00% 0.00% 44.55% 5.20% -46.39% -176.83% -1,066.65%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,036.87% -808.55%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,995.91% -861.33%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,995.91% -819.59%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,816.76% -819.59%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 92.10% 91.02% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -9,779.98% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -9,763.95% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 9,710.97% 0.00%
Return on Equity (ROE)		 -161.88% -49.67% -44.85% -47.97% -56.34% -69.01% -99.45%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -2,479.90% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -61.66% -62.81%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -56.12% -62.81%
Return on Common Equity (ROCE)		 469.67% -35.27% -44.85% -47.97% -56.34% -69.01% -99.45%
Return on Equity Simple (ROE_SIMPLE)		 55.80% -26.83% -39.07% -59.07% -51.39% -96.74% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -41 -80 -86 -93 -98 -73
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,397.14% -602.93%
Net Nonoperating Expense Percent (NNEP)		 -42.39% -13.33% -12.59% -11.75% -13.45% -16.03% -22.21%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -39.05% -74.40% -106.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 410.27% 184.56%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,685.64% 776.77%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,095.91% 961.33%
Earnings before Interest and Taxes (EBIT)		 -28 -57 -112 -115 -132 -140 -99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -56 -109 -112 -135 -143 -98
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 14.74 2.06 1.48 0.99 0.53 2.66
Price to Tangible Book Value (P/TBV)		 0.00 14.74 2.06 1.48 0.99 0.53 2.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 10.02 15.02
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.28 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 6.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.03 -1.02 -1.02 -1.00 -0.99 -1.18
Leverage Ratio		 1.28 1.07 1.06 1.09 1.15 1.23 1.58
Compound Leverage Factor		 1.28 1.07 1.06 1.09 1.15 1.23 1.58
Debt to Total Capital		 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 384.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -285.80% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.68 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.95 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.06 164.09 17.24 4.06 0.51 -5.53 -7.05
Noncontrolling Interest Sharing Ratio		 390.13% 28.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 4.18 19.41 15.37 9.42 10.79 5.30 1.99
Quick Ratio		 3.90 19.19 15.17 9.30 10.67 5.21 1.95
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -37 -80 -86 -103 -91 -41
Operating Cash Flow to CapEx		 -3,290.38% -7,435.91% -3,595.82% -2,773.40% -3,047.62% -13,467.02% -84,032.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.03 0.08
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.99 2.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -1.59 -6.13 -5.34 -6.29 4.16 -2.16 -35
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 7.00 -0.66
Increase / (Decrease) in Invested Capital		 0.00 -4.54 0.79 -0.96 10 -6.31 -32
Enterprise Value (EV)		 206 2,909 297 87 1.17 -63 79
Market Capitalization		 158 3,127 588 289 234 70 182
Book Value per Share		 ($29.61) $4.86 $6.06 $4.08 $4.32 $2.39 $1.09
Tangible Book Value per Share		 ($29.61) $4.86 $6.06 $4.08 $4.32 $2.39 $1.09
Total Capital		 17 212 286 195 237 131 69
Total Debt		 0.26 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -19 -218 -291 -202 -233 -134 -103
Capital Expenditures (CapEx)		 0.78 0.62 2.32 3.02 3.51 0.76 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.23 -8.88 -15 -19 -19 -23 -51
Debt-free Net Working Capital (DFNWC)		 16 209 276 183 214 110 53
Net Working Capital (NWC)		 15 209 276 183 214 110 53
Net Nonoperating Expense (NNE)		 7.89 16 32 29 29 29 26
Net Nonoperating Obligations (NNO)		 -19 -218 -291 -202 -233 -134 -103
Total Depreciation and Amortization (D&A)		 0.38 0.54 2.28 3.92 -2.30 -2.87 1.34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -333.71% -416.11%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,575.06% 434.09%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,575.06% 434.09%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.56) ($2.43) ($2.44) ($2.02) ($1.68) ($1.29)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 46.59M 47.63M 47.37M 60.36M 75.81M 76.96M
Adjusted Diluted Earnings per Share		 $0.00 ($4.56) ($2.43) ($2.44) ($2.02) ($1.68) ($1.29)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 46.59M 47.63M 47.37M 60.36M 75.81M 76.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.56) ($2.43) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 12.48M 46.05M 47.91M 54.92M 55.15M 63.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -41 -80 -86 -93 -98 -73
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,397.14% -602.93%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,995.91% -819.59%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.02% -0.27% 0.00% -2.30% -0.09% 0.00%

Quarterly Metrics And Ratios for Prelude Therapeutics

This table displays calculated financial ratios and metrics derived from Prelude Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 54,808,715.00 54,825,982.00 54,825,982.00 54,929,567.00 55,024,470.00 - 55,154,634.00 56,460,481.00 56,600,345.00 62,865,270.00 63,002,248.00
DEI Adjusted Shares Outstanding		 54,808,715.00 54,825,982.00 54,825,982.00 54,929,567.00 55,024,470.00 - 55,154,634.00 56,460,481.00 56,600,345.00 62,865,270.00 63,002,248.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.56 -0.61 -0.57 -0.63 -0.59 - -0.58 -0.55 -0.35 -0.26 -0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 116.67% 41.00% 0.00%
EBITDA Growth		 -11.49% -33.95% -16.71% -16.75% -2.36% 10.04% 3.00% 12.94% 40.79% 44.41% 67.12%
EBIT Growth		 -2.17% -30.51% -13.40% -14.16% -5.43% 9.49% -2.08% 10.10% 38.88% 42.72% 67.63%
NOPAT Growth		 -9.80% -11.96% -17.96% -14.71% -2.97% 9.49% -0.77% 13.37% 40.60% 48.72% 59.03%
Net Income Growth		 -2.17% -15.48% -13.40% -14.16% -5.43% 13.13% -2.08% 10.10% 38.88% 42.72% 67.63%
EPS Growth		 28.57% 25.00% 27.59% 14.81% 4.44% 17.78% 0.00% 10.87% 39.53% 45.95% 69.05%
Operating Cash Flow Growth		 -25.66% -2.84% -5.50% 16.67% -6.28% 12.02% -7.68% -13.09% 29.97% 211.45% 36.65%
Free Cash Flow Firm Growth		 -55.56% -63.34% 19.01% -1.09% 49.37% 52.55% 24.29% 20.11% 21.20% 216.73% 179.67%
Invested Capital Growth		 216.80% 166.05% 24.59% 0.00% -63.81% -151.87% -53.42% 7.81% 27.52% -1,504.50% -620.74%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 33.33% -100.00% 0.00% 0.00% -13.23% -18.79%
EBITDA Q/Q Growth		 -4.64% -19.40% 14.62% -9.45% 8.25% -4.93% -8.15% 1.77% 37.61% 16.14% 36.02%
EBIT Q/Q Growth		 -0.58% -22.12% 15.91% -10.53% 7.11% -4.83% -11.67% 2.66% 36.84% 16.57% 36.90%
NOPAT Q/Q Growth		 -3.05% -11.96% 8.12% -8.21% 7.50% 1.59% -2.29% 6.97% 36.58% 15.04% 18.28%
Net Income Q/Q Growth		 -0.58% -8.06% 4.97% -10.53% 7.11% 10.97% -11.67% 2.66% 36.84% 16.57% 36.90%
EPS Q/Q Growth		 16.67% 0.00% 6.67% -9.52% 6.52% 13.95% -13.51% 2.38% 36.59% 23.08% 35.00%
Operating Cash Flow Q/Q Growth		 7.17% 8.20% -34.83% 27.47% -18.38% 24.00% -65.02% 23.83% 26.69% 220.95% -193.80%
Free Cash Flow Firm Q/Q Growth		 -34.18% 3.03% 29.59% -10.35% 32.80% 9.13% -12.36% -16.43% 33.71% 234.61% -23.31%
Invested Capital Q/Q Growth		 0.00% -46.39% 112.03% -72.40% 15.34% -176.83% 290.44% -36.11% 36.42% -1,066.65% 38.19%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -1,089.37% -857.33% 0.00% 0.00% -297.68% -287.71% -226.68%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -1,145.87% -845.78% 0.00% 0.00% -314.12% -307.59% -309.54%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -1,075.70% -845.78% 0.00% 0.00% -303.46% -291.79% -226.75%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -1,075.70% -718.28% 0.00% 0.00% -303.46% -291.79% -226.75%
Tax Burden Percent		 100.00% 76.00% 100.00% 100.00% 100.00% 69.61% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 116.43% 100.00% 100.00% 100.00% 121.99% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -455.92% -4,144.30% 0.00% 0.00% -723.54% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -451.64% -4,141.54% 0.00% 0.00% -718.33% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 439.56% 4,119.07% 0.00% 0.00% 697.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.53% -56.34% -53.11% -71.24% -16.35% -25.23% 0.00% 0.00% -26.54% -99.45% -95.25%
Cash Return on Invested Capital (CROIC)		 -1,344.15% -2,479.90% -1,234.08% -8,389.94% -1,806.32% 0.00% -1,444.60% -3,747.32% -2,679.61% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -14.16% -26.13% 0.00% 0.00% -21.83% -22.36% -29.06%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -14.16% -22.19% 0.00% 0.00% -21.83% -22.36% -29.06%
Return on Common Equity (ROCE)		 -51.53% -56.34% -53.11% -71.24% -16.35% -25.23% 0.00% 0.00% -26.54% -99.45% -95.25%
Return on Equity Simple (ROE_SIMPLE)		 -49.27% 0.00% -59.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -26 -24 -26 -24 -24 -24 -23 -14 -12 -9.92
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -802.11% -592.04% 0.00% 0.00% -219.89% -215.31% -216.68%
Net Nonoperating Expense Percent (NNEP)		 -3.18% -3.18% -3.24% -9.70% -4.27% -2.76% -5.22% -6.87% -5.21% -3.64% -0.51%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.04% -11.41% -14.27% -15.38% -18.01% -23.48% -29.72% -24.42% -17.69% -16.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 263.97% 155.28% 0.00% 0.00% 80.15% 88.58% 112.58%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 981.90% 790.50% 0.00% 0.00% 333.97% 319.01% 296.97%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,245.87% 945.78% 0.00% 0.00% 414.12% 407.59% 409.54%
Earnings before Interest and Taxes (EBIT)		 -31 -37 -31 -35 -32 -34 -32 -31 -20 -16 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -38 -33 -36 -33 -34 -32 -31 -19 -16 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.71 0.99 1.23 1.15 0.73 0.53 0.41 0.60 1.39 2.66 3.58
Price to Tangible Book Value (P/TBV)		 0.71 0.99 1.23 1.15 0.73 0.53 0.41 0.60 1.39 2.66 3.58
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 37.97 10.02 6.05 6.53 7.76 15.02 12.89
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.28 6.58 12.10 0.00 0.00 0.00 0.00 7.42 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.53 6.52 8.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -0.97 -0.99 -0.97 -0.99 -0.96 -0.98 -0.97 -1.18 -1.11
Leverage Ratio		 1.10 1.15 1.12 1.23 1.15 1.23 1.24 1.31 1.36 1.58 1.60
Compound Leverage Factor		 1.10 1.34 1.12 1.23 1.15 1.50 1.24 1.31 1.36 1.58 1.60
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.35 1.64 2.02 0.07 -1.97 -3.54 -5.43 -7.43 -8.57 -5.11 -5.66
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.91 10.79 11.64 7.83 7.04 5.30 5.18 3.68 3.21 1.99 2.03
Quick Ratio		 13.65 10.67 11.45 7.71 6.91 5.21 5.01 3.50 3.02 1.95 1.95
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -38 -37 -26 -28 -19 -17 -20 -23 -15 20 16
Operating Cash Flow to CapEx		 -4,345.69% -2,088.40% -11,000.35% -6,422.56% -43,326.98% -39,139.62% -72,831.91% -130,375.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.04 0.07 0.08 0.13
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.43 0.99 1.02 1.04 1.65 2.04 3.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7.75 4.16 8.81 2.43 2.81 -2.16 4.10 2.62 3.58 -35 -21
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.57 7.00 1.08 2.77 3.29 -0.66 -1.94
Increase / (Decrease) in Invested Capital		 14 10 1.74 2.43 -4.95 -6.31 -4.71 0.19 0.77 -32 -25
Enterprise Value (EV)		 -61 1.17 58 29 -40 -63 -57 -28 27 79 134
Market Capitalization		 169 234 260 209 114 70 42 46 82 182 215
Book Value per Share		 $4.35 $4.32 $2.78 $3.32 $2.84 $2.39 $1.87 $1.34 $1.03 $1.09 $0.96
Tangible Book Value per Share		 $4.35 $4.32 $2.78 $3.32 $2.84 $2.39 $1.87 $1.34 $1.03 $1.09 $0.96
Total Capital		 238 237 211 182 156 131 103 76 59 69 60
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -231 -233 -202 -180 -154 -134 -99 -73 -55 -103 -82
Capital Expenditures (CapEx)		 0.59 1.13 0.29 0.36 0.06 0.05 0.05 0.02 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -19 -14 -20 -19 -23 -16 -17 -15 -51 -39
Debt-free Net Working Capital (DFNWC)		 218 214 188 159 134 110 83 56 40 53 43
Net Working Capital (NWC)		 218 214 188 159 134 110 83 56 40 53 43
Net Nonoperating Expense (NNE)		 7.24 6.91 7.39 8.73 8.21 5.05 7.86 8.70 5.43 4.31 0.46
Net Nonoperating Obligations (NNO)		 -231 -233 -202 -180 -154 -134 -99 -73 -55 -103 -82
Total Depreciation and Amortization (D&A)		 -1.32 -0.74 -1.12 -0.88 -0.41 -0.46 0.51 0.22 0.38 0.23 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -648.77% -333.71% -235.11% -246.40% -141.11% -416.11% -231.35%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 4,472.10% 1,575.06% 1,180.23% 799.54% 382.29% 434.09% 256.42%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 4,472.10% 1,575.06% 1,180.23% 799.54% 382.29% 434.09% 256.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.45) ($0.42) ($0.46) ($0.43) ($0.37) ($0.42) ($0.41) ($0.26) ($0.20) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 67.64M 60.36M 75.74M 75.76M 75.86M 75.81M 75.99M 75.99M 76.13M 76.96M 82.52M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.45) ($0.42) ($0.46) ($0.43) ($0.37) ($0.42) ($0.41) ($0.26) ($0.20) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 67.64M 60.36M 75.74M 75.76M 75.86M 75.81M 75.99M 75.99M 76.13M 76.96M 82.52M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.83M 54.92M 54.93M 55.02M 55.04M 55.15M 56.46M 56.60M 62.87M 63.00M 79.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -26 -24 -26 -24 -24 -24 -23 -14 -12 -9.92
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -802.11% -592.04% 0.00% 0.00% -219.89% -215.31% -216.68%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -1,075.70% -1,031.80% 0.00% 0.00% -303.46% -291.79% -226.75%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -2.30% -1.99% -2.22% -2.21% -0.09% -0.09% -0.02% 0.00% 0.00% -0.38%

Financials Breakdown Chart

Key Financial Trends

Prelude Therapeutics (NASDAQ: PRLD) continues to look like a development-stage biotech with meaningful cash resources, but also persistent losses and heavy cash burn. The latest quarter shows the company still has a substantial liquidity cushion, though revenue remains modest and operating expenses continue to exceed sales by a wide margin.

  • PRLD ended Q1 2026 with $84.6 million in total current assets, including $21.8 million in cash and equivalents and $59.8 million in short-term investments.
  • The company’s current assets still exceed total liabilities, with $60.2 million in common equity at the end of Q1 2026.
  • Q1 2026 revenue of $4.6 million was higher than the $0 reported in Q1 2025, showing continued monetization activity.
  • Operating cash flow improved sharply year over year, with Q1 2026 net cash from operations at -$21.7 million versus -$34.2 million in Q1 2025.
  • The company generated meaningful cash from investment activity in Q1 2026, supported by $8.5 million in sales/maturities of investments.
  • The balance sheet remains heavily dependent on marketable securities and other noncurrent operating assets rather than recurring operating cash generation.
  • Other income helped reduce losses in Q1 2026, contributing $3.8 million to pre-tax results.
  • Share count has risen over the last year, with weighted average basic shares at 82.5 million in Q1 2026 versus 75.9 million in Q1 2025, which can dilute per-share value.
  • Prelude remains unprofitable, posting a Q1 2026 net loss of $10.4 million.
  • Operating expenses continue to exceed revenue by a wide margin: Q1 2026 operating expenses were $18.8 million against revenue of just $4.6 million.
  • R&D spending was still high at $13.6 million in Q1 2026, which is typical for biotech but contributes to ongoing cash burn.
  • Cash and equivalents declined from $47.5 million in Q3 2025 to $21.8 million in Q1 2026, reflecting continued use of liquidity.
  • Over the past several quarters, the company has consistently reported large quarterly losses and negative operating cash flow, underscoring its dependence on financing and investment assets to fund operations.

Bottom line: Prelude Therapeutics still has a usable cash runway thanks to its investment portfolio and balance sheet, but the underlying business remains loss-making and cash-consuming. For retail investors, the key question is whether upcoming clinical or business developments can eventually translate into more durable revenue and reduced burn before liquidity becomes strained.

07/03/26 04:22 AM ETAI Generated. May Contain Errors.

Prelude Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prelude Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Prelude Therapeutics' net income appears to be on an upward trend, with a most recent value of -$99.50 million in 2025, rising from -$27.57 million in 2019. The previous period was -$127.17 million in 2024. See where experts think Prelude Therapeutics is headed by visiting Prelude Therapeutics' forecast page.

Prelude Therapeutics' total operating income in 2025 was -$104.57 million, based on the following breakdown:
  • Total Gross Profit: $12.14 million
  • Total Operating Expenses: $116.71 million

Over the last 6 years, Prelude Therapeutics' total revenue changed from $0.00 in 2019 to $12.14 million in 2025, a change of 1,214,000,000.0%.

Prelude Therapeutics' total liabilities were at $72.68 million at the end of 2025, a 65.0% increase from 2024, and a 1,401.6% increase since 2019.

In the past 6 years, Prelude Therapeutics' cash and equivalents has ranged from $12.47 million in 2024 to $218.31 million in 2020, and is currently $35.26 million as of their latest financial filing in 2025.

Over the last 6 years, Prelude Therapeutics' book value per share changed from -29.61 in 2019 to 1.09 in 2025, a change of -103.7%.


Related Companies

Financial statements for NASDAQ:PRLD last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel